Investor Presentaiton
Phase 2 Clinical Trial - Comparatively High-Risk, Poor Prognosis Population
Disease Burden Significantly Higher in Both Any-Line and First-Line MUM Population+
*
IDE196-001 Phase 2*
Darovasertib + Crizotinib
Tebentasfusp First-Line Phase 3#
Baseline Characteristics
Any-Line n=63 (%) First-Line n=20 (%)
< 65
35 (56)
10 (50)
Tebe Arm
n=252 (%)
64 Median
Control Arm^
n=126
66 Median
Age
≥65
28 (44)
10 (50)
F
32 (51)
9 (45)
124 (49)
64 (51)
Sex
M
31 (49)
11 (55)
128 (51)
62 (49)
0
43 (68)
14 (70)
192 (76)
85 (67)
ECOG PS
1
20 (32)
6 (30)
49 (19)
31 (25)
Normal
25 (40)
10 (50)
Baseline LDH
>ULN
38 (60)
10 (50)
90 (36)
46 (37)
≤3.0 cm
22 (35)
8 (40)
139 (55)
70 (56)
Largest metastatic lesion
3.1 to 8.0 cm
35 (56)
9 (45)
92 (37)
46 (37)
≥ 8.1 cm
6 (10)
3 (15)
21 (8)
Location of metastases
Hepatic Only
Extrahepatic Only
20 (32)
10 (50)
131 (52)
3 (5)
0
9 (4)
Hepatic and Extrahepatic
40 (64)
10 (50)
11
+ Cross-trial comparisons are not based on head-to-head studies and are presented for informational purposes; no direct comparisons are being made
*IDEAYA Data as of March 08, 2023 (based on preliminary analysis of unlocked database by investigator review)
# N Engl J Med 2021; 385:1196-1206; ECOG data missing in Tebentafusp and Control arm of 4% and 7% respectively
^Investigator Choice distribution in the control group: 103 (82%) received pembrolizumab, 16 (13%) received ipilimumab, and 7 (6%) received dacarbazine.
111 (44)
10 (8)
59 (47)
10 (8)
55 (44)
IDEA A
BIOSCIENCESView entire presentation